In line with Dexa Group's vision of to be a Respected International Healthcare Company, Medela Potentia participated in the International Finance Corporation (IFC) Global Private Health Conference 2025. The event, held by the IFC from February 18-20, 2025 in Nusa Dua, Bali, focused on "Impactful Investing for Your Tech-Enabled Accessible Health Systems, Breaking Barriers, Building Trust, Bridging Gaps" in global health.
The conference emphasized the importance of strengthening health systems in developing countries to address global health challenges. Key strategies included expanding access to health products and services, and improving disease prevention and treatment. The private sector plays a crucial role through impact investments in technology-driven business models that promote a sustainable health industry and contribute to better health outcomes.
Collaboration between the public and private sectors is essential to drive growth in the healthcare industry within developing countries. The IFC Global Private Health Conference 2025 was attended by representatives from global industries, including pharmaceuticals, hospitals, health technology companies, investment firms, and the Indonesian government.
Krestijanto Pandji, CEO of Medela Potentia, was a featured speaker during a talk show session titled "Building Bridges, Growing Health: Unlocking the Indonesia Health Sector Through Strategic Partnership and Investment – An Indonesia LifeScience Perspective."
Other speakers included Roy Himawan, Director of Primary Health Service Governance, Ministry of Health of the Republic of Indonesia; Silva Halim, Managing Director of Mandiri Sekuritas; Subir Sasak, Senior Industry Specialist, Pharma & Biotech, IFC; and Yuliana Indriati, Business Development Director of Biofarma. The session was moderated by Ridhi Gupta, Investor Officer at IFC.
In his remarks, Mr. Pandji emphasized the importance of the cold chain system in the distribution of health products. PT Medela Potentia, through its subsidiary PT Anugrah Argon Medica (AAM), has operated its own cold chain distribution facilities for over 25 years, ensuring product quality and safety.
He noted that building an independent cold chain infrastructure for each warehouse requires substantial investment. Therefore, Public-Private Partnerships (PPPs) can provide a solution for developing cold chain facilities that can be used to distribute health products widely.
"Cold chain is not easy and it is expensive. If each warehouse has to build its own, the cost is enormous. This could be an opportunity to build cold chain facilities that can be used for vaccines, pharmaceutical products, and medical devices," said Mr. Pandji.
Mr. Pandji also highlighted the importance of digitalization in ensuring the quality and authenticity of pharmaceutical products through the implementation of "Track and Trace" systems, similar to those in Europe. Under this system, each pharmaceutical product is assigned a QR code that can be traced by the Ministry of Health or the National Agency of Drug and Food Control (BPOM). The QR code provides transparent information about the product's location, manufacturer, active ingredients, and expiration date.
"Digitalization is essential to ensure that the products in circulation are genuine and of high quality," he explained. "With a track and trace system, each box has a QR code that allows tracking from the factory to the end user."
The IFC Global Private Health Conference 2025 is expected to foster collaboration between the public and private sectors to improve health services in Indonesia. With strategic investment and strong partnerships, the national health sector is expected to advance and provide safer and more affordable products for the community.